Identification of m7G-associated lncRNA prognostic signature for predicting the immune status in cutaneous melanoma

Abstract

RNA modifications, including RNA methylation, are widely existed in cutaneous melanoma (CM). Among epigenetic modifications, N7-methylguanosine (m7G) is a kind of modification at 5' cap of RNA which participate in maintaining the stability of mRNA and various cell biological processes. However, there is still no study concerning the relationship between CM and m7G methylation complexes, METTL1 and WDR4. Here, long non-coding RNA (lncRNAs) and gene expression data of CM from the Cancer Genome Atlas (TCGA) database were retrieved to identify differentially expressed m7G-related lncRNAs connected with overall survival of CM. Then, Cox regression analyses was applied to construct a lncRNA risk signature, the prognostic value of identified signature was further evaluated. As a result, 6 m7G-associated lncRNAs that were significantly related to CM prognosis were incorporated into our prognostic signature. The functional analyses indicated that the prognostic model was correlated with patient survival, cancer metastasis, and growth. Meanwhile, its diagnostic accuracy was better than conventional clinicopathological characteristics. The pathway enrichment analysis showed that the risk model was enriched in several immunity-associated pathways. Moreover, the signature model was significantly connected with the immune subtypes, infiltration of immune cells, immune microenvironment, as well as several m6A-related genes and tumor stem cells. Finally, a nomogram based on the calculated risk score was established. Overall, a risk signature based on 6 m7G-associated lncRNAs was generated which presented predictive value for the prognosis of CM patients and can be further used in the development of novel therapeutic strategies for CM.

A novel N7‐methylguanosine‐related long noncoding RNAs signature for predicting prognosis and immune microenvironment in gastric cancer patients

“…For example, some researchers have identified that the m 7 G-related lncRNA risk model can be an efficient prognostic tool and anti-tumor immunotherapy target for multiple cancer types, including colon carcinoma, 34 Lung Adenocarcinoma 35 and cutaneous melanoma. 36 In our study, the m 7 G-related lncRNAs risk model was constructed using three prognostic lncRNAs by bioinformatic analysis.…”

The role of lncRNAs in the tumor microenvironment and immunotherapy of melanoma

“…Recently, researchers have analyzed the expression data of melanoma in the TCGA database and established a prediction model between immune-related lncRNAs and the survival status of melanoma ( 86 , 87 ). The analysis in TCGA database indicated that 6 differentially expressed m7G-related lncRNAs have been identified, and a prognostic model was constructed for predicting the tumor growth, metastasis and survival status of patients ( 88 ). Another study found that a number of glycolysis-correlated lncRNAs show pivotal clinical effects by oncogenic pathways such as EMT and immune-related regulation ( 89 ).…”

m7G-related lncRNAs are potential biomarkers for predicting prognosis and immune responses in patients with oral squamous cell carcinoma

“…After reading and summarizing the published literature, 23 m7G regulatory factors were identified. The m7G regulatory factors include METTL1, WDR4, NSUN2, DCP2, DCPS, NUDT10, NUDT11, NUDT16, NUDT3, NUDT4, NUDT4B, AGO2, CYFIP1, EIF4E, EIF4E1B, EIF4E2, EIF4E3, GEMIN5, LARP1, NCBP1, NCBP2, NCBP3, EIF3D, EIF4A1, EIF4G3, IFIT5, LSM1, NCBP2 L, and SNUPN (Rong et al, 2022). A total of 16,773 lncRNAs were obtained in the OSCC data set of TCGA.…”